Develops genome-edited allogeneic cell therapies. Focuses on treatments for hematologic malignancies and solid tumors. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 11.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 8% of them.
Analysts' average target sits 294% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $11.2M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 43 buys and 8 sells. Management buying with its own money is usually read as a good sign.
A loss of $148.1M against $11.2M in annual sales.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CRBU sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CRBU is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (8/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.